Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269144 | 0.77 | LMNA (0.33) | LMNAPOLBMAPT | |
| SCHEMBL13080778 | 0.77 | ELANE (0.42) | ELANELMNAKDM4EPOLB | |
| SCHEMBL23896887 | 0.73 | ELANE (0.40) | ELANEKDM4EPOLB | |
| SCHEMBL25885453 | 0.72 | ELANE (0.41) | ELANELMNAKDM4EPOLB | |
| SCHEMBL12309182 | 0.72 | ELANE (0.49) | ELANEKDM4EPOLBALDH1A1MAPT | |
| SCHEMBL2705397 | 0.69 | LMNA (0.36) | ELANELMNAKDM4EALDH1A1MAPT | |
| SCHEMBL15935279 | 0.69 | — | — | |
| SCHEMBL12689675 | 0.69 | DYRK1A (0.31) | — | |
| SCHEMBL14788337 | 0.69 | ELANE (0.38) | ELANELMNAKDM4EPOLB | |
| SCHEMBL10220833 | 0.68 | KDM4E (0.56) | ELANELMNAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030442-A1 | COMBINATION THERAPIES | CAO ZHU ALEXANDER (US) | 2020-01-30 | — | — | US | disclosed |
| US-20170340733-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-11-30 | — | — | US | disclosed |
| US-20130096136-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-8415383-B2 | Substituted benzamidines as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-04-09 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-7626030-B2 | Compounds and methods of use | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | ELANE 2765/4885LMNA 3250/4885KDM4E 819/4885 |
| US-20200030442-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | ELANE 839/4885LMNA 2500/4885KDM4E 4340/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | ELANE 1818/4885LMNA 1817/4885KDM4E 2407/4885 |
| US-20170340733-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | ELANE 839/4885LMNA 2500/4885KDM4E 4340/4885 |
| US-20130096136-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | ELANE 2950/4885LMNA 4744/4885KDM4E 3367/4885 |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | ALK, CBR3, CBR1 | ELANE 1872/4885LMNA 2129/4885KDM4E 2671/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | ELANE 1818/4885LMNA 1817/4885KDM4E 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.